RAPT Therapeutics (NASDAQ:RAPT) Given New $13.00 Price Target at JPMorgan Chase & Co.

RAPT Therapeutics (NASDAQ:RAPT) had its target price trimmed by JPMorgan Chase & Co. from $15.00 to $13.00 in a research report released on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other equities analysts have also commented on the company. Evercore ISI initiated coverage on RAPT Therapeutics in a research note on Friday, February 16th. They issued an outperform rating on the stock. Wolfe Research assumed coverage on RAPT Therapeutics in a report on Thursday, February 15th. They issued an outperform rating and a $39.00 price target for the company. HC Wainwright lowered RAPT Therapeutics from a buy rating to a neutral rating in a research note on Wednesday, February 21st. Barclays decreased their price target on shares of RAPT Therapeutics from $35.00 to $13.00 and set an overweight rating on the stock in a research note on Wednesday, February 21st. Finally, Cantor Fitzgerald downgraded shares of RAPT Therapeutics from an overweight rating to a neutral rating in a report on Tuesday, February 20th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, RAPT Therapeutics presently has a consensus rating of Moderate Buy and a consensus price target of $25.67.

RAPT Therapeutics Stock Performance

RAPT opened at $8.93 on Wednesday. The firm has a market cap of $310.76 million, a P/E ratio of -2.94 and a beta of 0.47. The business has a 50 day moving average price of $16.56 and a 200 day moving average price of $16.91. RAPT Therapeutics has a twelve month low of $6.86 and a twelve month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.05. As a group, analysts anticipate that RAPT Therapeutics will post -3.21 earnings per share for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Hedge funds have recently modified their holdings of the stock. Credit Suisse AG lifted its stake in shares of RAPT Therapeutics by 2.0% during the second quarter. Credit Suisse AG now owns 39,018 shares of the company’s stock valued at $730,000 after acquiring an additional 771 shares during the period. Tower Research Capital LLC TRC raised its holdings in RAPT Therapeutics by 46.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,994 shares of the company’s stock worth $56,000 after purchasing an additional 953 shares during the last quarter. Northern Trust Corp lifted its position in RAPT Therapeutics by 0.3% during the 2nd quarter. Northern Trust Corp now owns 287,553 shares of the company’s stock valued at $5,377,000 after purchasing an additional 979 shares during the period. Legal & General Group Plc boosted its stake in shares of RAPT Therapeutics by 6.1% in the 3rd quarter. Legal & General Group Plc now owns 21,047 shares of the company’s stock valued at $350,000 after purchasing an additional 1,214 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of RAPT Therapeutics by 2.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 62,729 shares of the company’s stock worth $1,173,000 after buying an additional 1,418 shares during the period. 99.09% of the stock is owned by institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.